Targeting the Tumor Microenvironment with Gene-Engineered Immune Cells: Focus on CAR-Macrophages and CAR-NK Cells – A Review Article
Health Innovation Reports · 2025
DOI: 10.64048/hir.v1n3.007 ↗Abstract
The TME is a culprit of immunosuppression and a significant hurdle to long-term immunotherapeutic success in solid tumors, which are often associated with a dense stroma, hypoxia, and immunosuppressive myeloid and lymphoid cells. Conventional CAR-T cells tend to fail in this scenario as they are subjected to restricted trafficking, functional exhaustion, and inhibitory cues. Innate immune effectors including macrophages and natural killer (NK) cells are natural resident solid tumor infiltrates with strong cytotoxic and phagocytic potential, and thus represent promising chassis for CAR engineering. CARmacrophages (CAR-M) CAR-Ms can phagocytose tumor cells directly and modulate the TME towards inflammation and superior T cell priming, whereas CAR-NK cells have the advantage of combining antigen-specific targeting with innate recognition, ADCC, and outstanding safety profile. Here, we review recent preclinical and clinical progress in CAR-M and CAR-NK therapy, focusing on their potential to modulate the TME, discuss engineering approaches to resist TME-imposed challenges, and present new clinical trials. We conclude that CAR-M and CAR-NK platforms represent complementary strategies to turning “cold” tumors “hot”, but that enhanced persistence, trafficking, and on-target, off-tumor safety are needed.
EUVIMED